BI 1820237 for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Mar 2023: Trial registered, NCT05751226
  2. 11 Apr 2023: Trial started, NCT05751226

The trials

NCT05751226: A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

State
Completed
Phase
Phase 1
People
88 taking part
Started
11 Apr 2023
Primary completion
1 Aug 2024
Arms
BI 1820237 treatment group, BI 1820237 + semaglutide treatment group, BI 1820237 + BI 456906 treatment group
Results
None posted
  1. 2 Mar 2023: Trial registered
  2. 11 Apr 2023: Trial started
  3. 1 Aug 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.